ZIM
CORT icon

Zacks Investment Management’s Corcept Therapeutics CORT Stock Holding History

Zacks Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,001
Closed -$117K – 542
2019
Q1 		$117K Buy
+10,001
New +$124K ﹤0.01% 517
2016
Q4 		– Sell
-47,745
Closed -$310K – 655
2016
Q3 		$310K Buy
+47,745
New +$278K 0.01% 497
2016
Q2 		– Sell
-31,239
Closed -$146K – 640
2016
Q1 		$146K Buy
+31,239
New +$122K ﹤0.01% 572

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Zacks Investment Management's CORT Position: Q2 2019 in Review

Zacks Investment Management sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 10,001 shares — an estimated $117K sold.

Zacks Investment Management first reported a position in CORT in Q1 2016 and held it in 3 quarters. The position peaked at $310K in Q3 2016. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Zacks Investment Management reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Zacks Investment Management sold 10,001 Corcept Therapeutics shares in Q2 2019, an estimated $117K.
  • Zacks Investment Management first reported a position in Corcept Therapeutics in Q1 2016 and held it in 3 quarters.
  • Zacks Investment Management's Corcept Therapeutics position peaked at $310K in Q3 2016.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Zacks Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.